Patritumab Deruxtecan Elicits Durable Responses in EGFR-Mutated NSCLC

Patritumab deruxtecan displayed clinically meaningful and durable efficacy in patients with advanced EGFR-mutated non–small cell lung cancer who experienced progression following treatment with an EGFR-directed TKI and platinum-based chemotherapy.

Related Keywords

New York ,United States ,Singapore ,Memorial Sloan Kettering Cancer Center ,Daiichi Sankyo ,Helenaa Yu ,Lung Cancer ,Patritumab Deruxtecan ,Egfr ,Nsclc ,Non Small Cell Lung Cancer ,Egfr Mutated Nsclc ,Antibody Drug Conjugate ,Her3 Dxd ,Herthena Lung01 Trial ,World Conference On Lung Cancer ,Wclc ,D ,Omsk ,